Newfeed

Guardant360® CDx is the first blood-based companion diagnostic to be approved in Japan for the detection of EGFR exon 20 insertion mutations TOKYO, Aug. 30, 2024 /PRNewswire/ — Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representative Director: Mika Takaki), a leading precision oncol

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: